EUVIMEDEUVIMED entdecken
Open Access

Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer

Xiaoye Liu iD, Ryan Huang iD, Zhiqiang Ku iD, Jingjing Xie, Heyu Chen, Yubo He, Qi Lou, Chengcheng Zhang iD, Xing Yang, Cheryl Lewis iD, Jade Homsi, Ankit Gupta iD und 15 weitere

Science Immunology · 03.04.2026 · 11 (118)

DOI: 10.1126/sciimmunol.adt7832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 03.04.2026. Verfasst von Xiaoye Liu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Receptors, Immunologic, Claudins, Myeloid Cells, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Welch Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mechanisms underlying tumor cell–myeloid cell interactions in the tumor microenvironment (TME) remain unclear, and predictive biomarkers for patient response to myeloid checkpoint blockade are lacking. This study identified specific binding between tight junction claudins (CLDNs) and leukocyte immunoglobulin-like receptor subfamily B2 (LILRB2) and LILRB5. In multiple human cancer cohorts, the spatial proximity of LILRB2-positive macrophages to CLDN-expressing cancer cells correlated with clinical outcomes, highlighting this spatial relationship as a potential biomarker. In syngeneic LILRB2-transgenic and humanized mouse models, CLDN18.2-LILRB2 interactions triggered bidirectional signaling, enhanced the immunosuppressive activity of myeloid cells, and accelerated tumor progression. These effects were reversed by LILRB2 blockade. The CLDN-LILRB2 axis sustained immunosuppression by regulating NF-κB and STAT signaling pathways. Our findings reveal a mechanism of myeloid cell regulation by tight junction proteins in the TME, offering a rationale for targeting this pathway in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicClaudinsMyeloid CellsNeoplasmsMembrane GlycoproteinsAnimalsHumansMiceTumor MicroenvironmentSignal TransductionImmune ToleranceCell Line, TumorMice, Transgenic

Substanzen

Receptors, ImmunologicClaudinsLILRB2 protein, humanMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, USA.
  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Center for Alzheimer's and Neurodegenerative Diseases, UT Southwestern Medical Center, Dallas, TX, USA.
  • Quantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA.

ORCID-Profile: Xiaoye Liu, Ryan Huang, Zhiqiang Ku, Chengcheng Zhang, Cheryl Lewis, Ankit Gupta, Lei Dong, Liming Du, Hailong Yu, Qing Hu, Meng Fang, Bufan Li, Caroline Simith, Samuel John, Lin Xu, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Welch Foundation
  • Cancer Prevention and Research Institute of Texas
  • Leukemia and Lymphoma Society
  • Immune Onc Therapeutics Inc Sponsored Research

Zitieren

APA

Liu, X., Huang, R., Ku, Z., Xie, J., Chen, H., He, Y., Lou, Q., Zhang, C., Yang, X., Lewis, C., Homsi, J., Gupta, A., Dong, L., Chen, K., Tu, A., Du, L., Yu, H., Hu, Q., Fang, M., …, & Zhang, C. C. (2026). Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer. Science Immunology, 11(118). https://doi.org/10.1126/sciimmunol.adt7832

Vancouver

Liu X, Huang R, Ku Z, Xie J, Chen H, He Y, et al. Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer. Science Immunology. 2026;11(118). doi:10.1126/sciimmunol.adt7832

BibTeX
@article{Liu2026,
  author = {Liu, Xiaoye and Huang, Ryan and Ku, Zhiqiang and Xie, Jingjing and Chen, Heyu and He, Yubo and Lou, Qi and Zhang, Chengcheng and Yang, Xing and Lewis, Cheryl and Homsi, Jade and Gupta, Ankit and Dong, Lei and Chen, Kenian and Tu, Annabel and Du, Liming and Yu, Hailong and Hu, Qing and Fang, Meng and Li, Bufan and Khan, A E M Adan and Simith, Caroline and John, Samuel and Xu, Lin and Zhang, Ningyan and An, Zhiqiang and Zhang, Cheng Cheng},
  title = {Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer},
  journal = {Science Immunology},
  year = {2026},
  volume = {11},
  number = {118},
  doi = {10.1126/sciimmunol.adt7832}
}
Kostenlos starten →